Home
Patient
What is Precision Cancer Medicine?
How does Precision Cancer Medicine work?
Why is Precision Cancer Medicine Important?
Physician
Our Solutions
Types of Panels
Glossary
News
About Us
About Us
Our Team
Contact Us
Thursday 28 May 2020
Home
Patient
What is Precision Cancer Medicine?
How does Precision Cancer Medicine work?
Why is Precision Cancer Medicine Important?
Physician
Our Solutions
Types of Panels
Glossary
News
About Us
About Us
Our Team
Contact Us
Sitemap
Home
>
Sitemap
Thursday 28 May 2020
Menu
Home
Patient
What is Precision Cancer Medicine?
How does Precision Cancer Medicine work?
Why is Precision Cancer Medicine Important?
Physician
Our Solutions
Types of Panels
Glossary
News
About Us
About Us
Our Team
Contact Us
Latest News
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
FDA grants accelerated approval to pemigatinib for cholangiocarcinoma with an FGFR2 rearrangement or fusion
FGFR2 fusions appear to be much less frequent in tumours arising in the context of chronic liver fluke infection, the most common aetiology in SE Asia.
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update(2)
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]
Oncodna logo - wideToggle main menu visibility ENDOMETRIAL CANCER: Data from SGO 2020 indicate survival benefit for the addition of trastuzumab to standard chemo for those with advanced ERBB2-expressing (HER2+) disease (OS 24.4 versus 29.6 months) April 27, 2020 SCIENTIFIC Randomized phase II trial of carboplatin-paclitaxel compared to carboplatin-paclitaxel-trastuzumab in advanced or recurrent uterine serous carcinomas that overexpress Her2/neu (NCT01367002): Updated survival analysis
Findings from three clinical trial arms of precision medicine released at 2018 (at ASCO meeting in Chicago) on the study developed by NCI and ECOG-ACRIN:
: NCI-MATCH, a phase 2 clinical trial, seeks to determine whether targeted therapies for people whose tumors have certain gene mutations will be effective regardless of their cancer type, using ...
